Home DNA Damage/DNA Repair DNA/RNA Synthesis inhibitor - COVID-19 inhibitor - Influenza Virus inhibitor Favipiravir (T-705) For research use only.

Favipiravir (T-705)

Favipiravir (T-705) is a potent and selective RNA-dependent RNA polymerase inhibitor, used to treat influenza virus infections.

Favipiravir (T-705) Chemical Structure

Favipiravir (T-705) Chemical Structure

CAS: 259793-96-9

Selleck's Favipiravir (T-705) has been cited by 20 Publications

2 Customer Reviews

Purity & Quality Control

Batch: Purity: 99.97%
99.97

Other DNA/RNA Synthesis Products

Related compound libraries

Choose Selective DNA/RNA Synthesis Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDCK Antiviral assay 3 days Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New York/34/2008(H1N1)) harboring M2 L26I mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysi, EC50 = 0.19 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Ann Arbor/6/1960(H2N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 0.38 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Florida/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis, EC50 = 0.45 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus B/Memphis/20/1996 harboring neuraminidase R152K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic ana, EC50 = 0.57 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Swine/South Dakota/03/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet, EC50 = 0.83 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/Brazil/1633/2008(H1N1)) harboring neuraminidase Q136K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 0.83 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/05/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 0.83 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/New York/18/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsco, EC50 = 0.89 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days , EC50 = 0.89 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet , EC50 = 0.96 μM. 20350949
MDCK Antiviral assay Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Bethesda/956/2006(H3N2)) harboring neuraminidase R292K mutant and M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication af, EC50 = 1.21 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/Mexico/4604/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsco, EC50 = 1.21 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus B/Memphis/20/1996 infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.21 μM. 20350949
MDCK Antiviral assay Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/chicken/Vietnam/NCVD103/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I222T mutant infected in MDCK cells assessed as inhibition of viral replication after, EC50 = 1.27 μM. 20350949
MDCK Antiviral assay Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by virus yield reduction assay, EC90 = 1.3 μM. 17194832
MDCK Antiviral assay 1 hr Antiviral activity against Influenza B virus (B/Brisbane/60/2008) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 1.32 μM. 23419738
MDCK Antiviral assay Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza A virus (A/Vietnam/HN30408/2005 N294S clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase N294S mutant infected in MDCK cells assessed as inhibition of viral , EC50 = 1.341 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/07/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 1.4 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/Rochester/01/2001) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.4 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Georgia/17/2006(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.46 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/turkey/VA/4529/2002 (H7N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.53 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Florida/21/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc, EC50 = 1.59 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/duck/Vietnam/NCVD93/2007 clade 2.3.4 (H5N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using cry, EC50 = 1.59 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus (B/Rochester/01/2001) harboring neuraminidase D198N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic, EC50 = 1.72 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Brazil/1067/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 1.85 μM. 20350949
MDCK Antiviral assay 1 hr Antiviral activity against Influenza B virus (B/Lee/40) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 1.93 μM. 23419738
MDCK Antiviral assay 1 hr Antiviral activity against Influenza B virus (B/Panama/45/1990) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 1.94 μM. 23419738
MDCK Antiviral assay 3 days Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/04/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 1.97 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/swine/Michigan/09/2007 (H1N2)) harboring M2 V27I, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic a, EC50 = 2.23 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Ecuador/5179/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 2.48 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Georgia/20/2006(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc, EC50 = 2.55 μM. 20350949
MDCK Antiviral assay Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay, EC50 = 2.6 μM. 17194832
MDCK Antiviral assay Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by virus yield reduction assay, EC90 = 2.6 μM. 17194832
MDCK Antiviral assay 24 hrs Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as inhibition of neuraminidase activity using 2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid substrate pretreated with cells for 24 hrs followed by vira, EC50 = 2.7 μM. 27120583
MDCK Antiviral assay 1 hr Antiviral activity against Influenza B virus (B/Taiwan/2/62) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 2.84 μM. 23419738
MDCK Antiviral assay 3 days Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Wisconsin/16/2008(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micros, EC50 = 2.87 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza A virus (A/Idaho/01/2009(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysi, EC50 = 2.93 μM. 20350949
MDCK Antiviral assay Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Luhansk/18/2008(H1N1)) harboring neuraminidase H274Y mutant and M2 G34E mutant infected in MDCK cells assessed as inhibition of viral replication afte, EC50 = 2.93 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-, oseltamivir-, zanamivir-resistant Influenza B virus (B/Illinois/03/2008) harboring neuraminidase E119A mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis u, EC50 = 3 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Washington/10/2008(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic anal, EC50 = 3.25 μM. 20350949
MDCK Antiviral assay Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/duck/Vietnam/NCVD94/2007 clade 2.3.4 (H5N1)) harboring neuraminidase I117V mutant infected in MDCK cells assessed as inhibition of viral replication a, EC50 = 3.38 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/California/27/2007(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 3.63 μM. 20350949
MDCK Antiviral assay Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by virus yield reduction assay, EC90 = 3.8 μM. 17194832
MDCK Antiviral assay Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119I mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral , EC50 = 3.95 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/Illinois/47/2005) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 4.01 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New Hampshire/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic an, EC50 = 4.08 μM. 20350949
MDCK Antiviral assay Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Vietnam/HN30408/2005 H274Y clade 1 (H5N1)) harboring M2 L26I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition, EC50 = 4.14 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Massachusetts/03/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic an, EC50 = 4.2 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Washington/01/2007(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analy, EC50 = 4.46 μM. 20350949
MDCK Antiviral assay Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay, EC50 = 4.5 μM. 17194832
MDCK Antiviral assay 3 days Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Swine/Texas/14/2008 (H1N1)) harboring M2 V27T, V28D mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic anal, EC50 = 4.52 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/Santiago/5248/2008(H1N1)) harboring neuraminidase D198E mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micr, EC50 = 4.7 μM. 20350949
MDCK Antiviral assay 1 hr Antiviral activity against Influenza A virus (A/Hong kong/8/1968(H2N3)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 4.71 μM. 23419738
MDCK Antiviral assay 3 days Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/New Jersey/15/2007(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by micr, EC50 = 4.9 μM. 20350949
Vero Antiviral assay 7 to 8 days Antiviral activity against Junin virus Candid-1 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days, EC50 = 5 μM. 17606691
MDCK Antiviral assay 3 days Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/North Carolina/02/ 2009(H1N1)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic, EC50 = 5.03 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus (B/Michigan/20/2005) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic , EC50 = 5.03 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Vietnam/1203/2004 clade 1 (H5N1)) harboring M2 L26I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by mic, EC50 = 5.22 μM. 20350949
MDCK Antiviral assay Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119V mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral , EC50 = 5.22 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus (B/New York/22/2008) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain, EC50 = 5.3 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Wuhan/395/1995-like (H3N2)) harboring neuraminidase E119V mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by mi, EC50 = 5.41 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Wuhan/395/1995-like (H3N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal viole, EC50 = 5.99 μM. 20350949
Vero Antiviral assay 7 to 8 days Antiviral activity against Pichinde virus An 4763 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days, EC50 = 6 μM. 17606691
Vero Antiviral assay 7 to 8 days Antiviral activity against Tacaribe virus TRVL11573 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days, EC50 = 6 μM. 17606691
MDCK Antiviral assay Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/pdm/Washington/29/2009 (H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral re, EC50 = 6.62 μM. 20350949
MDCK Antiviral assay 1 hr 3 days Antiviral activity against Influenza A virus (A/Taiwan/1/1986(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity at 1 hr post-infection measured after 3 days by fluorescein-diacetate based fluorimetric analysis, EC50 = 6.95 μM. 23419738
MDCK Antiviral assay Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by virus yield reduction assay, EC90 = 7.7 μM. 17194832
MDCK Antiviral assay 3 days Antiviral activity against Influenza virus B/Ned/537/05 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by formazan-based MTS assay, EC50 = 8.3 μM. 29906392
MDCK Antiviral assay 3 days Antiviral activity against Influenza virus B/Ned/537/05 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by microscopic analysis, EC50 = 9 μM. 29906392
MDCK Antiviral assay 3 days Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New York/107/2003(H7N2)) harboring M2 V28A, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic , EC50 = 10.2 μM. 20350949
MDCK Antiviral assay Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay, EC50 = 11.5 μM. 17194832
MDCK Antiviral assay Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay, EC50 = 12.1 μM. 17194832
Vero-A Antiviral assay Antiviral activity against Chikungunya virus venturini isolate (Italy 2008) infected in African green monkey Vero-A cells assessed as inhibition of viral-induced cytopathic effect measured on day 7 post infection by MTS/PMS assay, EC50 = 16 μM. 28689975
MDCK Antiviral assay Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/pdm/Illinois/10/2009(H1N1)) harboring M2 V28I, S31N mutant and neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral repli, EC50 = 22.48 μM. 20350949
MDCK Antiviral assay 3 days Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by microscopic analysis, EC50 = 24 μM. 29906392
Vero-A Antiviral assay Antiviral activity against Chikungunya virus 899 infected in African green monkey Vero-A cells assessed as inhibition of viral-induced cytopathic effect measured on day 7 post infection by MTS/PMS assay, EC50 = 25 μM. 28689975
Vero-A Antiviral assay Antiviral activity against Chikungunya virus LR2006-OPY1 infected in African green monkey Vero-A cells assessed as inhibition of viral-induced cytopathic effect measured on day 7 post infection by MTS/PMS assay, EC50 = 25 μM. 28689975
MDCK Antiviral assay 3 days Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by formazan-based MTS assay, EC50 = 26 μM. 29906392
MDCK Antiviral assay Antiviral activity against 0.001 MOI adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/Mexico/4604/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture at, NULL = NULL μM. 20350949
MDCK Antiviral assay Antiviral activity against 0.001 MOI adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/04/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture , NULL = NULL μM. 20350949
MDCK Antiviral assay 128 uM Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/Mexico/4604/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture at 128 uM af, NULL = NULL μM. 20350949
MDCK Antiviral assay 128 uM Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/04/2009(H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as determination of viral titer in cell culture at 128 uM , NULL = NULL μM. 20350949
Vero Antiviral assay 6400 uM up to 12 hrs Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as time required for inhibition of viral replication at 6400 uM up to 12 hrs post-viral infection, NULL = NULL μM. 18955536
MDCK Antiviral assay 0 to 2 hrs Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 0 to 2 hrs post-infection by RT-qPCR method based time of addition assay, NULL = NULL μM. 30192544
MDCK Antiviral assay 5 to 8 hrs Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 5 to 8 hrs post-infection by RT-qPCR method based time of addition assay, NULL = NULL μM. 30192544
MDCK Antiviral assay 0 to 10 hrs Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 0 to 10 hrs post-infection by RT-qPCR method based time of addition assay, NULL = NULL μM. 30192544
MDCK Antiviral assay 2 to 5 hrs Inhibition of influenza A virus infected in MDCK cells assessed as inhibition of viral load treated with compound at 2 to 5 hrs post-infection by RT-qPCR method based time of addition assay, NULL = NULL μM. 30192544
MDCK Antiviral assay 10 uM up to 8 hrs Antiviral activity against Influenza A virus (A/chicken/Hubei/327/2004(H5N1)) infected in MDCK cells assessed as inhibition of early stages of viral replication at 10 uM up to 8 hrs by crystal violet staining based plaque reduction assay dependent time-of, NULL = NULL μM. 30292897
MDCK Antiviral assay 100 uM 12 hrs Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as inhibition of one cycle viral RNA synthesis at 100 uM preincubated with cells for 12 hrs followed by viral infection measured after 10 hrs post infection by RT-qPCR metho, NULL = NULL μM. 29906392
MDCK Antiviral assay 250 uM 10 hrs Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as inhibition of one cycle viral RNA sytheis at 250 uM added together with virus and measured at 10 hrs post infection by RT-qPCR method, NULL = NULL μM. 29906392
Click to View More Cell Line Experimental Data

Biological Activity

Description Favipiravir (T-705) is a potent and selective RNA-dependent RNA polymerase inhibitor, used to treat influenza virus infections.
Targets
RNA-dependent RNA polymerase [1]
In vitro
In vitro Favipiravir shows anti-influenza virus activities with IC50 ranged from 0.013 to 0.48 μg/ml for the influenza A viruses, from 0.039 to 0.089 μg/ml for the influenza B viruses, and from 0.030 to 0.057 μg/ml for the influenza C viruses. In mammalian cell lines (MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells), Favipiravir shows no cytotoxicity at concentrations up to 1,000 μg/ml. [1] In MDCK cells inoculated with seasonal influenza A (H1N1) viruses, Favipiravir induces lethal mutagenesis. [2]
Cell Research Cell lines MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells
Concentrations 1000 μg/mL
Incubation Time 3 days
Method The cytotoxicity of T-705 is evaluated by an assay with XTT. XTT is converted to aqueous formazan by an enzyme in MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells. The compounds are diluted to the appropriate concentrations (volume, 100 μl) with test medium (EMEM containing 10% FCS) in 96-well culture plates in which each well contains a concentration of 2 × 103 cells/100 μL. The test plates are incubated for 3 days at 37°C in 100% humidity and 5% CO2. After 3 days, 50 μl of the XTT reagent (1 mg/ml in FCS-free EMEM containing 5 mM phenazine methosulfate) is added, and the reaction product is assayed by measurement of the absorbance at 450 nm with a microplate reader. Cytotoxicity is expressed as the 50% cell-inhibitory concentration (CC50).
Experimental Result Images Methods Biomarkers Images PMID
Growth inhibition assay Survival Cell viability 26711718
IHC H&E Staining NiV nucleoprotein LASV antigen H&E stain 29765101
Immunofluorescence rNiV-Gluc 29765101
In Vivo
In vivo In influenza virus-infected mice, Favipiravir (200 mg/kg/day, p.o.) protects the mice from death from influenza virus infection. [1] In mice experimentally infected with Ebola virus, Favipiravir efficiently blocks viral production, reaching an antiviral effectiveness of 95% and 99.6% at 2 and 6days after initiation of treatment, respectively. [3]
Animal Research Animal Models Mice infected with influenza virus A/PR/8/34
Dosages 200 mg/kg/day
Administration p.o.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06024421 Not yet recruiting Infectious Disease|Pharmacology Institut National de la Santé Et de la Recherche Médicale France|FUJIFILM Toyama Chemical Co. Ltd. November 2023 Phase 1
NCT05940545 Recruiting CCHF Liverpool School of Tropical Medicine July 12 2023 Phase 1|Phase 2
NCT04907682 Completed Lassa Fever Bernhard Nocht Institute for Tropical Medicine|University of Hamburg-Eppendorf|Alliance for International Medical Action|Institut National de la Santé Et de la Recherche Médicale France|University of Bordeaux|Federal Medical Centre Owo|Irrua Specialist Teaching Hospital July 30 2021 Phase 2

Chemical lnformation & Solubility

Molecular Weight 157.1 Formula

C5H4FN3O2
CAS No. 259793-96-9 SDF Download Favipiravir (T-705) SDF
Smiles C1=C(N=C(C(=O)N1)C(=O)N)F
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 31 mg/mL ( (197.32 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 2 mg/mL

Ethanol : 2 mg/mL


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Favipiravir (T-705) | Favipiravir (T-705) supplier | purchase Favipiravir (T-705) | Favipiravir (T-705) cost | Favipiravir (T-705) manufacturer | order Favipiravir (T-705) | Favipiravir (T-705) distributor